HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Lancet Oncol 2022 Apr 27;[EPub Ahead of Print], R Motzer, C Porta, B Alekseev, SY Rha, TK Choueiri, MJ Mendez-Vidal, SH Hong, A Kapoor, JC Goh, M Eto, L Bennett, J Wang, JJ Pan, TL Saretsky, RF Perini, CS He, K Mody, D CellaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.